Status:
COMPLETED
A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria
Lead Sponsor:
Evommune, Inc.
Conditions:
Chronic Inducible Urticaria
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This phase 2a trial will evaluate the safety and efficacy of EVO756 in subjects with chronic inducible urticaria, including symptomatic dermographism and cold urticaria.
Eligibility Criteria
Inclusion
- Confirmed diagnosis of chronic inducible urticaria for at least 3 months.
- Positive response following provocation using the TempTest or FricTest at Screening and Day 1.
Exclusion
- History of diseases other than chronic inducible urticaria or chronic spontaneous urticaria with urticaria or angioedema symptoms, such as urticarial vasculitis, erythema multiforme, cutaneous mastocytosis (urticaria pigmentosa), and hereditary or acquired angioedema.
- Concurrent use of certain medications, including antihistamines.
- Any clinically significant disease, or other skin disease or skin markings (e.g., extensive scarring, tattoos), that might confound the evaluation of safety or efficacy.
Key Trial Info
Start Date :
August 14 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 8 2025
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06603220
Start Date
August 14 2024
End Date
May 8 2025
Last Update
June 18 2025
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
Cahaba Dermatology & Skin Health Center, LLC
Birmingham, Alabama, United States, 35244
2
California Allergy and Asthma Medical Group
Los Angeles, California, United States, 90025
3
Integrative Skin Science and Research
Sacramento, California, United States, 95815
4
West Dermatology Research Center
San Diego, California, United States, 92121